Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2026 Earnings Call Transcript

Fisher & Paykel Healthcare held its FY2026 first-half results conference call on 25 November 2025 covering the six months ended 30 September 2025; management including CEO Lewis Gradon and CFO Lyndal York presented and the company lodged its interim report with the NZX and ASX. The article provides only the call introduction, participant list and filing notice and contains no revenue, earnings, guidance or other financial figures — investors should review the interim report and filings for detailed P&L, cash flow and any guidance that could influence the stock.

Analysis

Market structure: Fisher & Paykel Healthcare (OTCPK:FSPKF / NZX:FPH) and peers with high recurring consumables (filters, masks) are the primary beneficiaries as hospital and home-respiratory demand stabilizes into winter; one‑off, elective-capex suppliers (large hospital-equipment OEMs) are the relative losers as buyers prefer proven recurring-revenue vendors. Pricing power should be intact for differentiated respiratory products, supporting gross-margin resilience of ~200–400 bps versus commoditized ventilators; inventory normalization suggests supply is no longer the bottleneck but demand seasonality will drive near-term revenue swings.

Risk assessment: Tail risks include an FDA/CE regulatory action or a large product recall (low probability, high impact), adverse reimbursement changes (timeline 6–18 months), or litigation around consumables (multi-year exposure). Immediately (days) expect muted stock moves around the interim release; short-term (weeks–months) hospital procurement cadence and flu/COVID waves will drive order volatility; long-term (quarters–years) secular adoption of home respiratory therapy and recurring consumables underpin steady cashflow. Hidden dependencies include payer reimbursements and FX translation (NZD moves >2% materially shift reported USD revenue); catalysts are FY26 guidance updates, major contract wins, and new product approvals.

Trade implications: Establish a measured 2–3% long position in FSPKF/FPH within 30 days targeting +15–25% in 12 months with a hard stop at −12% to capture recurring-revenue resilience; complement with purchase of Jan 2027 10–15% OTM calls sized at 30–50% of the equity position to lever potential upside around product approvals. For relative value, consider a 1.5% pair trade long FPH / short RMD (ResMed) over 6–12 months if you expect faster hospital/acute respirator growth versus consumer CPAP saturation; unwind if spread tightens to <5% or if RMD issues broaden.

Contrarian angle: The market may underappreciate margin tailwinds from continued supply-chain cost reduction and consumables stickiness — a scenario where consensus expects 'post‑pandemic normalization' but FPH converts higher installed base into recurring revenue, driving 5–10% upside to consensus EPS over 12 months. Conversely, an overdone safety trade into broadly labeled “defensive” medtech could be wrong if regulators or reimbursement changes occur; watch NZD/USD moves >2%, regulatory notices, and guidance revisions as triggers to reassess positions.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in OTCPK:FSPKF (or NZX:FPH) within 30 days; target +15–25% over 12 months, place a stop-loss at −12% to limit downside given regulatory/seasonal risk.
• Buy Jan 2027 FSPKF calls ~10–15% OTM sized at 30–50% of the cash-equity position to leverage potential upside from FY26 guidance updates or product approvals; cap premium spend at 1% of portfolio.
• Implement a 1.5% pair trade: long FPH / short RMD (ResMed) for 6–12 months to express relative strength in hospital/acute respiratory vs consumer CPAP; close if the spread narrows to <5% or after 12 months.
• Reduce exposure to large elective-procedure dependent hospital-equipment stocks (e.g., Medtronic/MDT, Philips/PHG) by 1–2% over the next quarter and redeploy into medtech names with >50% recurring consumables revenue to lower capex-cycle sensitivity.